Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04224688 · ClinicalTrials.gov registry record · Phase 3
A Study to Assess the Efficacy, Safety, and Tolerability of Rozanolixizumab in Adult Study Participants With Persistent or Chronic Primary Immune Thrombocytopenia (ITP)
A Phase 3 study, sponsored by UCB Biopharma SRL.
- Terminated
- Registry status
- Phase 3
- Development phase
- 30
- Enrollment target
NCT04224688 is a Phase 3 study that was terminated before completion, run by UCB Biopharma SRL. The registered enrollment target is 30 participants.
The verdict
NCT04224688, a Phase 3 study, was terminated before completion, sponsored by UCB Biopharma SRL.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 30 participants
- Enrollment target
Study Summary
The purpose of this study is to demonstrate the clinical efficacy of rozanolixizumab in maintenance treatment and assess safety and tolerability of rozanolixizumab in adult study participants with primary immune thrombocytopenia (ITP).
Interventions
- OTHER Placebo
- DRUG Rozanolixizumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2020-06-03 |
| Est. Completion | 2022-05-05 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04224688
The ClinicalTrials.gov registry entry for NCT04224688 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is UCB Biopharma SRL, which has 82 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT04224688 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04224688 about?
NCT04224688 is a clinical study titled "A Study to Assess the Efficacy, Safety, and Tolerability of Rozanolixizumab in Adult Study Participants With Persistent or Chronic Primary Immune Thrombocytopenia (ITP)". The purpose of this study is to demonstrate the clinical efficacy of rozanolixizumab in maintenance treatment and assess safety and tolerability of rozanolixizumab in adult study participants with primary immune thrombocytopenia (ITP).
What is the current status of trial NCT04224688?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 30 participants. The study started on 2020-06-03. Estimated completion is 2022-05-05.
What interventions are being tested in trial NCT04224688?
The interventions under investigation include: Placebo (OTHER), Rozanolixizumab (DRUG).
Who is sponsoring clinical trial NCT04224688?
This trial is sponsored by UCB Biopharma SRL, which has 82 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.